Procter & Gamble [PGHL] vs Sun Pharma Advanced [SPARC] Detailed Comparison
Procter & Gamble
NSE
Loading...
Sun Pharma Advanced
NSE
Loading...
TLDR: Quick Comparison Summary
Based on 19 vital metrics comparison: Procter & Gamble wins in 8 metrics, Sun Pharma Advanced wins in 2 metrics, with 0 ties. Procter & Gamble appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Procter & Gamble | Sun Pharma Advanced | Better |
|---|---|---|---|
| P/E Ratio (TTM) | 29.39 | -14.64 | Sun Pharma Advanced |
| Price-to-Book Ratio | 3.97 | N/A | N/A |
| Debt-to-Equity Ratio | N/A | -1.24 | N/A |
| PEG Ratio | 2.52 | 2.79 | Procter & Gamble |
| EV/EBITDA | 16.14 | -16.23 | Sun Pharma Advanced |
| Profit Margin (TTM) | 15.16% | -45.53% | Procter & Gamble |
| Operating Margin (TTM) | N/A | -199.95% | N/A |
| Return on Equity | N/A | 157.88% | N/A |
| Return on Assets (TTM) | N/A | -49.05% | N/A |
| Free Cash Flow (TTM) | $2.07B | $-3.71B | Procter & Gamble |
| Dividend Yield | 2.35% | N/A | N/A |
| 1-Year Return | 10.67% | -32.98% | Procter & Gamble |
| Price-to-Sales Ratio (TTM) | 5.46 | 70.39 | Procter & Gamble |
| Enterprise Value | $223.80B | $52.79B | Procter & Gamble |
| EV/Revenue Ratio | 1.62 | 73.56 | Procter & Gamble |
| Gross Profit Margin (TTM) | 52.78% | 36.82% | Procter & Gamble |
| Revenue per Share (TTM) | N/A | $2 | N/A |
| Earnings per Share (Diluted) | N/A | $-10.56 | N/A |
| Beta (Stock Volatility) | N/A | 0.35 | N/A |
Performance
Key Stats
Valuation
Financials
Short Interest
Dividends
Procter & Gamble vs Sun Pharma Advanced Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Procter & Gamble | -0.30% | -0.89% | -1.58% | 14.75% | 10.15% | 11.32% |
| Sun Pharma Advanced | -1.81% | -5.82% | -4.66% | 1.26% | -8.16% | -24.43% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Procter & Gamble | 10.67% | 30.66% | 39.46% | 606.94% | 703.72% | 1,264.75% |
| Sun Pharma Advanced | -32.98% | -33.23% | -13.74% | -62.66% | 57.68% | -47.74% |
Performance & Financial Health Analysis: Procter & Gamble vs Sun Pharma Advanced
| Metric | PGHL | SPARC |
|---|---|---|
| Market Information | ||
| Market Cap | N/A | ₹50.52B |
| Market Cap Category | N/A | Mid cap |
| 10 Day Avg. Volume | N/A | 540,737 |
| 90 Day Avg. Volume | N/A | 573,050 |
| Last Close | ₹5,810.50 | ₹151.66 |
| 52 Week Range | ₹4,863.00 - ₹6,175.50 | ₹109.30 - ₹241.00 |
| % from 52W High | -5.91% | -37.07% |
| All-Time High | ₹7,500.00 (Feb 08, 2021) | ₹875.00 (Apr 24, 2006) |
| % from All-Time High | -22.53% | -82.67% |
| Growth Metrics | ||
| Quarterly Revenue Growth | N/A | 0.64% |
| Quarterly Earnings Growth | N/A | 0.64% |
| Financial Health | ||
| Profit Margin (TTM) | 0.15% | -0.46% |
| Operating Margin (TTM) | N/A | -2.00% |
| Return on Equity (TTM) | N/A | 1.58% |
| Debt to Equity (MRQ) | N/A | -1.24 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | N/A | ₹-6.69 |
| Cash per Share (MRQ) | N/A | ₹0.06 |
| Operating Cash Flow (TTM) | N/A | ₹-3,602,930,944 |
| Levered Free Cash Flow (TTM) | N/A | ₹-1,261,192,192 |
| Dividends | ||
| Last 12-Month Dividend Yield | 2.35% | N/A |
| Last 12-Month Dividend | ₹140.00 | N/A |
Valuation & Enterprise Metrics Analysis: Procter & Gamble vs Sun Pharma Advanced
| Metric | PGHL | SPARC |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | 29.39 | -14.64 |
| Forward P/E | 28.41 | 2.79 |
| PEG Ratio | 2.52 | 2.79 |
| Price to Sales (TTM) | 5.46 | 70.39 |
| Price to Book (MRQ) | 3.97 | N/A |
| Market Capitalization | ||
| Market Capitalization | ₹219.41B | ₹50.52B |
| Enterprise Value | ₹223.80B | ₹52.79B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 1.62 | 73.56 |
| Enterprise to EBITDA | 16.14 | -16.23 |
| Risk & Other Metrics | ||
| Beta | N/A | 0.35 |
| Book Value per Share (MRQ) | N/A | ₹-6.69 |
Financial Statements Comparison: Procter & Gamble vs Sun Pharma Advanced
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | PGHL | SPARC |
|---|---|---|
| Revenue/Sales | ₹3.11B | ₹271.90M |
| Cost of Goods Sold | ₹987.20M | ₹171.80M |
| Gross Profit | ₹2.12B | ₹100.10M |
| Research & Development | N/A | N/A |
| Operating Income (EBIT) | ₹755.50M | ₹-561.30M |
| EBITDA | ₹840.30M | ₹-531.80M |
| Pre-Tax Income | ₹785.30M | ₹-606.70M |
| Income Tax | ₹173.50M | ₹-9.00M |
| Net Income (Profit) | ₹611.80M | ₹-597.70M |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | PGHL | SPARC |
|---|---|---|
| Cash & Equivalents | ₹1.82B | ₹19.60M |
| Total Current Assets | ₹5.26B | ₹261.90M |
| Total Current Liabilities | ₹2.15B | ₹3.74B |
| Long-Term Debt | ₹48.10M | ₹1.07B |
| Total Shareholders Equity | ₹5.37B | ₹-2.17B |
| Retained Earnings | N/A | N/A |
| Property, Plant & Equipment | ₹1.11B | ₹987.00M |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | PGHL | SPARC |
|---|---|---|
| Operating Cash Flow | ₹711.00M | N/A |
| Capital Expenditures | ₹-32.30M | N/A |
| Free Cash Flow | ₹459.90M | N/A |
| Debt Repayment | N/A | N/A |
| Common Stock Repurchase | N/A | N/A |
Short Interest & Institutional Ownership Analysis
| Metric | PGHL | SPARC |
|---|---|---|
| Shares Short | N/A | N/A |
| Short Ratio | N/A | N/A |
| Short % of Float | N/A | N/A |
| Average Daily Volume (10 Day) | N/A | 540,737 |
| Average Daily Volume (90 Day) | N/A | 573,050 |
| Shares Outstanding | N/A | 324.52M |
| Float Shares | N/A | 91.74M |
| % Held by Insiders | N/A | 0.73% |
| % Held by Institutions | N/A | 0.02% |
Dividend Analysis & Yield Comparison: Procter & Gamble vs Sun Pharma Advanced
| Metric | PGHL | SPARC |
|---|---|---|
| Last 12-Month Dividend | ₹140.00 | N/A |
| Last 12-Month Dividend Yield | 2.35% | N/A |
| 3-Year Avg Annual Dividend | ₹98.83 | N/A |
| 3-Year Avg Dividend Yield | 0.99% | N/A |
| 3-Year Total Dividends | ₹296.50 | N/A |
| Ex-Dividend Date | Feb 21, 2025 | N/A |